TY - JOUR
T1 - The role of epsilon PKC in acute and chronic diseases
T2 - Possible pharmacological implications of its modulators
AU - Capuani, Barbara
AU - Pacifici, Francesca
AU - Pastore, Donatella
AU - Palmirotta, Raffaele
AU - Donadel, Giulia
AU - Arriga, Roberto
AU - Bellia, Alfonso
AU - Di Daniele, Nicola
AU - Rogliani, Paola
AU - Abete, Pasquale
AU - Sbraccia, Paolo
AU - Guadagni, Fiorella
AU - Lauro, Davide
AU - Della-Morte, David
N1 - Funding Information:
This work has been supported by following grants: European Social Fund, under the Italian Ministry of Education, University and Research PON03PE_00146_1/10 BIBIOFAR (FG, DDM), Research Project 2009 grant, Fondazione Roma; ASI N 2013-084-R0, COREA Research Project, Italian Space Agency (DL). All authors approve this submission and do not have any conflict of interest with any third party related to this work.
Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Epsilon Protein kinase C (εPCK) is a particular kinase that, when activated, is able to protect against different stress injuries and therefore has been proposed to be a potential molecular target against acute and chronic diseases. Particular attention has been focused on εPCK for its involvement in the protective mechanism of Ischemic Preconditioning (IPC), a powerful endogenous mechanism characterized by subthreshold ischemic insults able to protect organs against ischemic injury. Therefore, in the past decades several εPCK modulators have been tested with the object to emulate εPCK mediate protection. Among these the most promising, so far, has been the ΨεRACK peptide, a homologous of RACK receptor for εPKC, that when administrated can mimic its effect in the cells. However, results from studies on εPCK indicate controversial role of this kinase in different organs and diseases, such as myocardial infarct, stroke, diabetes and cancer. Therefore, in this review we provide a discussion on the function of εPCK in acute and chronic diseases and how the different activators and inhibitors have been used to modulate its activity. A better understanding of its function is still needed to definitively target εPCK as novel therapeutic strategy.
AB - Epsilon Protein kinase C (εPCK) is a particular kinase that, when activated, is able to protect against different stress injuries and therefore has been proposed to be a potential molecular target against acute and chronic diseases. Particular attention has been focused on εPCK for its involvement in the protective mechanism of Ischemic Preconditioning (IPC), a powerful endogenous mechanism characterized by subthreshold ischemic insults able to protect organs against ischemic injury. Therefore, in the past decades several εPCK modulators have been tested with the object to emulate εPCK mediate protection. Among these the most promising, so far, has been the ΨεRACK peptide, a homologous of RACK receptor for εPKC, that when administrated can mimic its effect in the cells. However, results from studies on εPCK indicate controversial role of this kinase in different organs and diseases, such as myocardial infarct, stroke, diabetes and cancer. Therefore, in this review we provide a discussion on the function of εPCK in acute and chronic diseases and how the different activators and inhibitors have been used to modulate its activity. A better understanding of its function is still needed to definitively target εPCK as novel therapeutic strategy.
KW - Acute diseases
KW - Cancer
KW - Chronic diseases
KW - Epsilon PKC
KW - Epsilon PKC modulators
KW - Ischemic preconditioning
KW - Metabolism
UR - http://www.scopus.com/inward/record.url?scp=84979650200&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979650200&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2016.07.029
DO - 10.1016/j.phrs.2016.07.029
M3 - Review article
C2 - 27461137
AN - SCOPUS:84979650200
VL - 111
SP - 659
EP - 667
JO - Pharmacological Research
JF - Pharmacological Research
SN - 1043-6618
ER -